Literature DB >> 15855454

Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953.

Charles R Rinaldo1.   

Abstract

Poliomyelitis has gone from being one of the worst scourges of the 20th century to nearing eradication in the 21st. This success is well known to be attributable to the Salk inactivated and Sabin attenuated poliovirus vaccines.However, before introduction of these vaccines, William McDowall Hammon of the University of Pittsburgh Graduate School of Public Health led the first major breakthrough in prevention of the disease by using passive immunization in one of the earliest double-blind, placebo-controlled clinical trials. This study provided the first evidence that antibodies to poliovirus could prevent the disease in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855454      PMCID: PMC1449257          DOI: 10.2105/AJPH.2004.040790

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  37 in total

1.  Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases.

Authors:  W M HAMMON; L L CORIELL; E H LUDWIG; R M McALLISTER; A E GREENE; G E SATHER; P F WEHRLE
Journal:  J Am Med Assoc       Date:  1954-09-04

2.  Experimental studies on passive immunization against poliomyelitis. III. Passive-active immunization and pathogenesis after virus feeding in chimpanzees.

Authors:  D BODIAN
Journal:  Am J Hyg       Date:  1953-07

3.  Poliomyelitis virus in human blood during the minor illness and the asymptomatic infection.

Authors:  D M HORSTMANN; R W MCCOLLUM
Journal:  Proc Soc Exp Biol Med       Date:  1953-03

4.  Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 3. Preliminary report of results based on clinical diagnosis.

Authors:  W M HAMMON; L L CORIELL; P F WEHRLE; C R KLIMT; J STOKES
Journal:  J Am Med Assoc       Date:  1952-10-25

5.  Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues.

Authors:  J F Enders; T H Weller; F C Robbins
Journal:  Science       Date:  1949-01-28       Impact factor: 47.728

6.  Patenting the Sun. Polio and the Salk Vaccine. Jane S. Smith. Morrow, New York, 1990. 413 pp. + plates. $22.95.

Authors:  P M Mazumdar
Journal:  Science       Date:  1990-11-09       Impact factor: 47.728

7.  Vaccination Against Acute Anterior Poliomyelitis.

Authors:  J A Kolmer
Journal:  Am J Public Health Nations Health       Date:  1936-02

8.  Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types.

Authors:  D BODIAN; I M MORGAN; H A HOWE
Journal:  Am J Hyg       Date:  1949-03

9.  The association of parenteral injections with poliomyelitis.

Authors:  R F KORNS; R M ALBRECHT; F B LOCKE
Journal:  Am J Public Health Nations Health       Date:  1952-02

10.  Poliomyelitis virus in blood of orally infected monkeys and chimpanzees.

Authors:  D M HORSTMANN
Journal:  Proc Soc Exp Biol Med       Date:  1952-03
View more
  9 in total

1.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

2.  An Urgent Need for "Common Cold Units" to Study COVID-19.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

3.  COVID-19: The Need for Immunoprevention at Industrial Scale.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

4.  The clinical trials on gamma globulin for polio: victims of marketing success

Authors:  Stephen E Mawdsley
Journal:  CMAJ       Date:  2017-07-24       Impact factor: 8.262

Review 5.  Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.

Authors:  Puja Kumari; Kajal Rawat; Lekha Saha
Journal:  Curr Pharmacol Rep       Date:  2020-07-18

6.  COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.

Authors:  Scott B Halstead; Ramesh Akkina
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

Review 7.  Treatment of Argentine hemorrhagic fever.

Authors:  Delia A Enria; Ana M Briggiler; Zaida Sánchez
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

8.  Coronavirus disease 2019 (COVID-19): current status and future perspectives.

Authors:  Heng Li; Shang-Ming Liu; Xiao-Hua Yu; Shi-Lin Tang; Chao-Ke Tang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

Review 9.  What are the drugs having potential against COVID-19?

Authors:  Kaan Kucukoglu; Nagihan Faydalı; Dilek Bul
Journal:  Med Chem Res       Date:  2020-09-10       Impact factor: 1.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.